Develops therapeutic candidates for oncology, focusing on various cancer types. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
Sales run at $62.9M a year. A small number, but proof the product has real buyers.
There is $529.2M in the vault; even if every debt were paid off, $519.1M would remain.
A loss of $204.6M against $62.9M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 33/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 34/100.
On our five-subject report card, NUVB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NUVB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (43/100) says the stock isn’t cheap.